Search

Your search keyword '"Trembling, P"' showing total 81 results

Search Constraints

Start Over You searched for: Author "Trembling, P" Remove constraint Author: "Trembling, P"
81 results on '"Trembling, P"'

Search Results

2. The fate of indeterminate liver lesions: What proportion are precursors of hepatocellular carcinoma?

3. The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease

4. Association between skirt size and chronic liver disease in post-menopausal women: a prospective cohort study within the United Kingdom Trial of Ovarian Cancer Screening (UKCTOCS)

6. Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

13. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

14. The UK-PBC Risk Scores: Derivation and Validation of a Scoring System for Long-Term Prediction of End-Stage Liver Disease in Primary Biliary Cholangitis

16. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection

17. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis

21. P1198 : Histological stage is relevant for risk-stratification in primary biliary cirrhosis

22. O022 : The UK-PBC risk score: Derivation and validation of a risk score to predict liver events in the UK-PBC research cohort

23. The UK-PBC risk score: Derivation and validation of a risk score to predict liver events in the UK-PBC research cohort

25. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

29. PWE-138 Treatment Of Patients with Chronic Hepatitis C Genotype 1 and Advanced Fibrosis with Protease Inhibitors- Il28B Discordance Results in Early Viral Decline but Late Relapse: Abstract PWE-138 Table

30. 1224 TIMING AND CHARACTERISTICS OF DRUG RESISTANCE MUTATIONS (DRMS) IN CHRONIC HEPATITIS C PATIENTS DURING AND AFTER TREATMENT WITH PROTEASE INHIBITOR THERAPY AT A SINGLE CENTRE

37. Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C

41. TMC435for the treatment of chronic hepatitis C

42. Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats

44. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

45. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

46. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.

47. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.

48. Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure.

49. Complexities of HCV management in the new era of direct-acting antiviral agents.

Catalog

Books, media, physical & digital resources